Senesco Technologies SNTI today announced that it has agreed to terms and executed a non-binding
Letter of Intent to merge with Fabrus, Inc (“Fabrus”), a privately-held,
biotechnology company focused on expanding the clinical impact of
antibodies by addressing drug targets resistant to traditional antibody
discovery methods. Fabrus is committed to developing highly innovative
treatments to impact multiple diseases. Its research and technology is
published in the highly respected scientific journals Nature
Biotechnology and Cell.
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in